Cempra Completes Enrollment of Solitaire-Oral Phase 3 Trial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cempra Completes Enrollment of Solitaire-Oral Phase 3 Trial

CHAPEL HILL, N.C., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP ) today announced the completion of enrollment of the global Solitaire-Oral Phase 3 clinical trial of oral solithromycin in adult patients with moderate to moderately severe community-acquired bacterial pneumonia (CABP). Top-line efficacy and safety data are expected to be announced during the first quarter of 2015.

Key facts :

  • Community-acquired bacterial pneumonia (CABP) is the number one cause of death from an infection, particularly for the very young and old http://www.cdc.gov/abcs/reports-findings/surv...pneu09.pdf . Patients hospitalized for CABP face a mortality rate of 23% http://www.uspharmacist.com/continuing_educat...id/109254/ .
  • Community-acquired bacterial pneumonia (CABP) is one of the most common bacterial infections resulting in five to 10 million cases. http://www.ncbi.nlm.nih.gov/pubmed/?term=Clin...3A+S27-S72 and almost three million hospitalizations per year in the U.S. (source: 2011 HCUP, ARHQ.gov) resulting in approximately 29 million hospital days of antibiotic therapy (source: AMR Hospital Data, IMA, NPA, NDTI).
  • Over 40% of Streptococcus pneumoniae strains, the primary CABP pathogen, in the U.S. are resistant to macrolides http://www.dmidjournal.com/article/S0732-8893...7/abstract .
  • The Phase 3 study is a double-blind, placebo-controlled and global multi-center study that randomized 860 patients with PORT-II to PORT-IV CABP to receive either oral solithromycin, an 800 mg loading dose followed by 400 mg once daily for a total of five days, or once-daily oral administration of 400 mg of moxifloxacin for seven days. The primary endpoint is non-inferiority of early response at 72 hours in the intent-to-treat (ITT) population.
  • Secondary endpoints include the early response rate in the microbiological ITT population and the clinical success rates in the ITT and clinically-evaluable populations five to 10 days after the last dose of study drug.
  • More information can be found at http://www.clinicaltrials.gov/ct2/show/NCT019...cin&rank=2 .

Quote :

Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra said, "This is the first of our two Solitaire global Phase 3 trials to complete patient enrollment. In addition to learning about the safety and efficacy of solithromycin, we expect to learn much about the pathogens and their antibiotic susceptibility patterns that cause CABP. In this study, many patients have PORT III to PORT IV pneumonia and could have been admitted according to normal practice, but could be treated on an outpatient basis. Outpatient treatment could provide an economic advantage to the hospital as well as convenience and confidence in patients that the oral antibiotic they are given could treat their infection. Our second ongoing trial, Solitaire-IV, will provide information on switching hospitalized patients from intravenous solithromycin to oral solithromycin with the goal of not only sending patients home earlier but sending them home on the same drug that they started on when they were admitted in the hospital. We are looking forward to announcing top-line results of Solitaire-Oral, expected during the first quarter of 2015, and providing guidance on the anticipated timing of enrollment completion of Solitaire-IV following the northern hemisphere winter season."

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin also recently entered a Phase 3 clinical trial for uncomplicated Neisseria gonorrhoeae and chlamydia. Taksta™ (CEM-102) is Cempra's second product candidate, which completed a Phase 2 clinical trial for prosthetic joint infections. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com .

Please Note : This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the costs, timing, regulatory review and results of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our anticipated capital expenditures and our estimates regarding our capital requirements; our ability to obtain FDA approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including solithromycin and Taksta; our ability to produce and sell any approved products and the price we are able realize for those products; our ability to retain and hire necessary employees and to staff our operations appropriately; our ability to compete in our industry; our dependence on the success of solithromycin and Taksta; innovation by our competitors; and our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

Investor and Media Contacts: Robert E. Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 Andreas Marathovouniotis Russo Partners LLC (212) 845-4235

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 168

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 99

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 183

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 149

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 150

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 46

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading

Top 5 Most Recently Viewed Articles

Chuyuan Group's Transformative Journey Towards Sustainable Success

Updated Category News Views 226

Chuyuan Group's Path to Sustainability and Growth In recent years, Chuyuan Group has significantly transformed its operations, embracing high-quality development in response to the evolving regulatory landscape. As the industry landscape changes, companies like Chuyuan must adapt to remain competitive and environmentally responsible. Understanding the Shift: Old Yang and...

Continue Reading
Adani Bonds Face Downgrade Risk Amid U.S. Bribery Scandal

Updated Category News Views 355

Fitch Ratings Puts Adani Group Bonds on Negative Watch In a significant move, Fitch Ratings has placed bonds from various units of the Adani Group on a watchlist for potential downgrades. This action follows serious allegations against the conglomerate's top executives, who are facing U.S. charges related to bribery and fraud. Implications of the Watch Status Fitch's...

Continue Reading
Investigation of Arbor Realty Trust: What Investors Should Know

Updated Category News Views 81

Understanding the Investigation of Arbor Realty Trust Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into claims related to Arbor Realty Trust, Inc. (NYSE: ABR). Investors who have suffered losses exceeding $100,000 while investing in Arbor are encouraged to get in touch for more information and support. Who Should Reach Out to...

Continue Reading
Qualcomm's Strategic Move: Potential Intel Acquisition Talks

Updated Category News Views 185

Qualcomm's Interest in Intel's Assets Recently, Qualcomm has made headlines by showing interest in buying parts of Intel. This move seems to be a strategic effort by Qualcomm to strengthen its presence in the competitive technology market, especially within the chip manufacturing sector. Shifting Market Dynamics Intel, a leader in chip production, is currently facing...

Continue Reading
Refined Energy Corp Expands Partnership with Eagle Plains Resources

Updated Category News Views 113

Refined Energy Corp Strengthens Its Partnership Refined Energy Corp announces an important amendment to its agreement with Eagle Plains Resources Ltd. The key focus of this amendment is to enhance their collaboration on the Dufferin Project, a project located in Canada's Athabasca Basin, known for its rich mineral deposits. Details of the Amended Agreement In a recent...

Continue Reading